Fortress Biotech reports Q2 2026 results as partnered pipeline advances on multiple fronts
Crystalys raised $130 million for dotinurad's Phase 3 program while AstraZeneca reported positive subgroup data for anselamimab, as Fortress's cash balance grew to $196.6 million.
SEC filing